Derek M. Meisner Esq., J.D.
Net Worth
Last updated:
What is Derek M. Meisner Esq., J.D. net worth?
The estimated net worth of Mr. Derek M. Meisner Esq., J.D. is at least $3,001,281 as of 17 Aug 2022. He owns shares worth $432,576 as insider, has earned $171,405 from insider trading and has received compensation worth at least $2,397,300 in X4 Pharmaceuticals, Inc..
What is the salary of Derek M. Meisner Esq., J.D.?
Mr. Derek M. Meisner Esq., J.D. salary is $479,460 per year as Chief Legal Officer & Corporation Sec. in X4 Pharmaceuticals, Inc..
How old is Derek M. Meisner Esq., J.D.?
Mr. Derek M. Meisner Esq., J.D. is 54 years old, born in 1971.
What stocks does Derek M. Meisner Esq., J.D. currently own?
As insider, Mr. Derek M. Meisner Esq., J.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | Chief Legal Officer & Corporation Sec. | 145,155 | $2.98 | $432,576 |
What does X4 Pharmaceuticals, Inc. do?
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Derek M. Meisner Esq., J.D. insider trading
X4 Pharmaceuticals, Inc.
Mr. Derek M. Meisner Esq., J.D. has made 8 insider trades between 2020-2022, according to the Form 4 filled with the SEC. Most recently he sold 8,334 units of XFOR stock on 17 Aug 2022.
The largest trade he's ever made was exercising 15,909 units of XFOR stock on 11 Feb 2022. As of 17 Aug 2022 he still owns at least 145,155 units of XFOR stock.
X4 Pharmaceuticals key executives
X4 Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Paula Ragan Ph.D. (55) Founder, Chief Executive Officer, Pres, Sec. & Director
- Mr. Adam S. Mostafa (45) Chief Financial Officer, Treasurer & Assistant Sec.
- Mr. Derek M. Meisner Esq., J.D. (54) Chief Legal Officer & Corporation Sec.